British journal of clinical pharmacology
-
To study the pharmacokinetics of orally and intravenously administered ketobemidone in critically ill patients. ⋯ The disposition of ketobemidone is highly variable in critically ill patients. In order to ensure sufficient analgesia and avoid toxicity, therapeutic monitoring should be employed when using ketobemidone in this group of patients.
-
Br J Clin Pharmacol · Dec 2002
Randomized Controlled Trial Clinical TrialNo effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.
In rodent and primate studies, urotensin II is an extremely potent vasoconstrictor peptide with effects in the central aortic and arterial vasculature as well as on cardiac function. The aim of the present study was to assess systemic haemodynamic responses to intravenous urotensin II infusion in humans. ⋯ Intravenous urotensin II infusion did not affect systemic haemodynamics or arterial stiffness, despite achieving an approximately 100-fold increase in plasma immuno-reactivity. We conclude that urotensin II is unlikely to have a physiological role in the short term regulation of vascular tone or blood pressure in man. Further confirmatory studies with urotensin II receptor antagonists are required.